Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

\xe2\x80\x9cThrough my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH.